Orphanet: CARDINAL: Un ensayo de fase 23 sobre la eficacia y seguridad de la bardoxolona metilo en pacientes con síndrome de Alport
x

Search for a clinical trial

* (*) mandatory field

CARDINAL: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - ES (terminated)

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : No
  • Status : Terminated trial
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Reata pharmaceuticals
    • Phase : II - III
  • Principal investigator of clinical trial

  • INFORMATION NOT PROVIDED
  • Institution: Information not provided - ES
  • ADDRESS: NOT PROVIDED - ES
  • SPAIN
  • More information
  • Phone  : 
    Information not provided - ES
  • Fax  : -
  • Investigator of clinical trial

  • INFORMATION NOT PROVIDED
  • Servicio de Nefrologa
  • Hospital Universitari Vall d'Hebron
  • Paseo Vall d'Hebron, 119-129
  • 08035 BARCELONA
  • SPAIN
  • More information
  • Phone  : 34 93 489 30 00
  • Fax  : -
  • Website
  • Contact secretary  :
  • Investigator of clinical trial

  • INFORMATION NOT PROVIDED
  • Servicio de Nefrologa
  • Hospital Clnico Universitario Virgen de la Arrixaca
  • Carretera Cartagena-Madrid s/n
  • 30120 EL PALMAR, MURCIA
  • SPAIN
  • More information
  • Phone  : 34 968 36 95 00
  • Fax  : 34 968 36 97 76
  • Website
Last update: December 2020

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.